{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T15:32:47Z","timestamp":1788535967713,"version":"build-2803163510"},"reference-count":40,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T00:00:00Z","timestamp":1704153600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Atea Pharmaceuticals, Inc"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Investigational Drugs"],"published-print":{"date-parts":[[2024,1,2]]},"DOI":"10.1080\/13543784.2024.2305137","type":"journal-article","created":{"date-parts":[[2024,1,24]],"date-time":"2024-01-24T13:55:31Z","timestamp":1706104531000},"page":"9-17","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":11,"title":["Bemnifosbuvir (BEM, AT-527), a novel nucleotide analogue inhibitor of the hepatitis C virus NS5B polymerase"],"prefix":"10.1080","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-7662-1616","authenticated-orcid":false,"given":"Xiao-Jian","family":"Zhou","sequence":"first","affiliation":[{"name":"Departments of Preclinical and Clinical Development, Atea Pharmaceuticals, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven S","family":"Good","sequence":"additional","affiliation":[{"name":"Departments of Preclinical and Clinical Development, Atea Pharmaceuticals, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith","family":"Pietropaolo","sequence":"additional","affiliation":[{"name":"Departments of Preclinical and Clinical Development, Atea Pharmaceuticals, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Huang","sequence":"additional","affiliation":[{"name":"Departments of Preclinical and Clinical Development, Atea Pharmaceuticals, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adel","family":"Moussa","sequence":"additional","affiliation":[{"name":"Departments of Preclinical and Clinical Development, Atea Pharmaceuticals, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet MJ","family":"Hammond","sequence":"additional","affiliation":[{"name":"Departments of Preclinical and Clinical Development, Atea Pharmaceuticals, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Pierre","family":"Sommadossi","sequence":"additional","affiliation":[{"name":"Departments of Preclinical and Clinical Development, Atea Pharmaceuticals, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2024,1,24]]},"reference":[{"key":"e_1_3_5_2_1","unstructured":"World Health Organization. Hepatitis C key facts. 2020 [cited 2020 Sep 24]. Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-c"},{"key":"e_1_3_5_3_1","unstructured":"Centers for Disease Control and Prevention. Viral Hepatitis Surveillance \u2013 United States 2018 Atlanta (GA): 2020 [cited 2020 Sep 4]. https:\/\/www.cdc.gov\/hepatitis\/statistics\/SurveillanceRpts.htm"},{"key":"e_1_3_5_4_1","unstructured":"AASLD-IDSA. HCV guidance: recommendations for testing managing and treating hepatitis C. 2022 [cited 2023 Jul 5]. Available from: https:\/\/www.hcvguidelines.org\/"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.07.025"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.30225"},{"key":"e_1_3_5_7_1","unstructured":"U.S. Food and Drug Administration. FDA warns about rare occurrence of serious liver injury with use of hepatitis C medicines mavyret zepatier and vosevi in some patients with advanced liver disease. 2019 [cited 2020 Sep 3]. Available from: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-warns-about-rare-occurrence-serious-liver-injury-use-hepatitis-c-medicines-mavyret-zepatier-and"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.4904"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2020.100138"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12985-015-0414-1"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep4.1060"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.12882"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0227104"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01201-19"},{"key":"e_1_3_5_15_1","volume-title":"The International Liver Congress","author":"Mungur O","year":"2020","unstructured":"Mungur O, Berliba E, Bourgeois S, et al. A combination of AT-527, a potent pan-genotypic guanosine nucleotide prodrug, and daclatasvir was well-tolerated and effective in HCV-infected subjects. London (UK): The International Liver Congress; [cited 2020 Aug 27-29]. Available from: https:\/\/easl.eu\/event\/the-digital-international-liver-congress-2020\/"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.12068"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00318-16"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/toxsci\/kfw211"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2013.11.008"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jit562"},{"key":"e_1_3_5_21_1","volume-title":"Poster 1861-A. Presented at the American Association for the Study of Liver Diseases 2023 Annual Meeting","author":"Huang Q","unstructured":"Huang Q, Good SS, Cai D, et al. Bemnifosbuvir and ruzasvir are potent HCV DAAs with favorable antiviral profiles against major HCV NS5A and NS5B RAVs supporting use in combination. Poster 1861-A. Presented at the American Association for the Study of Liver Diseases 2023 Annual Meeting, 2023 Nov 10-14, Boston (USA)."},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02479-20"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1093\/pnasnexus\/pgad256"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01922-15"},{"key":"e_1_3_5_25_1","volume-title":"The Liver Meeting","author":"Zhou XJ","unstructured":"Zhou XJ, Berliba E, Bogus M, et al. AT-527, a purine nucleotide prodrug, exhibits potent pan-genotypic antiviral activity in HCV-infected subjects with cirrhosis. The Liver Meeting; 2018 Nov 9-13;San Francisco (CA). https:\/\/ateapharma.com\/wp-content\/uploads\/2020\/08\/48X72LandscapeAASLD201820181023final.pdf"},{"key":"e_1_3_5_26_1","volume-title":"The Liver Meeting","author":"Zhou XJ","year":"2019","unstructured":"Zhou XJ, Berliba E, Jucov A, et al. HCV viral kinetic analysis predicts shorter treatment duration with AT- 527, a purine nucleotide prodrug with potent pan-genotypic antiviral activity in HCV-infected subjects regardless of cirrhosis status. The Liver Meeting; 2019 Nov 8-12; Boston (MA). https:\/\/ateapharma.com\/wp-content\/uploads\/2020\/08\/48X72LandscapeAASLD2019VKFinal.pdf"},{"key":"e_1_3_5_27_1","volume-title":"The International Liver Congress","author":"Zhou XJ","year":"2018","unstructured":"Zhou XJ, Berliba E, Vanhoutte F, et al. AT-527, a pan-genotypic purine nucleotide prodrug, exhibits potent antiviral activity in subjects with chronic hepatitis C. The International Liver Congress; 2018 Apr 11-15; Paris (France). https:\/\/ateapharma.com\/wp-content\/uploads\/2020\/08\/90cmX140cmLandscapeEASL201820180406final.pdf"},{"key":"e_1_3_5_28_1","volume-title":"The Liver Meeting","author":"Zhou XJ","unstructured":"Zhou XJ, Vanhoutte F, Berliba E, et al. A phase 1a study of AT-527, a novel pan- genotypic purine nucleotide prodrug inhibitor of hepatitis C virus (HCV). The Liver Meeting; 2017 Oct 20-24; Washington (D.C). https:\/\/ateapharma.com\/wp-content\/uploads\/2020\/08\/36x60HorizontalTemplatev12Atea-Pharmaceuticals-AASLDFinal20171020.pdf"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9092702"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0163644"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.3851\/IMP2733"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2015.97"},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.coviro.2016.06.005"},{"key":"e_1_3_5_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2011.05.003"},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00530-12"},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1512610"},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1512612"},{"key":"e_1_3_5_38_1","volume-title":"Poster 411. Presented at the International Conference on Antiviral Research","author":"Good SS","unstructured":"Good SS, Lin K, Luo S, et al. The combination of bemnifosbuvir (BEM) and Ruzasvir (RZR), the HCV NS5B and NS5A inhibitors, demonstrates potent in vitro synergistic antiviral activity and in vivo preclinical safety without adverse interactions. Poster 411. Presented at the International Conference on Antiviral Research; 2023 Mar 13-17; Lyon (France)."},{"key":"e_1_3_5_39_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.6b01310"},{"key":"e_1_3_5_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.13132"},{"key":"e_1_3_5_41_1","volume-title":"Poster 1879. Presented at the Liver Meeting","author":"Zhou XJ","unstructured":"Zhou XJ, Morelli G, Montrond M, et al. Lack of pharmacokinetic drug-drug-interaction between bemnifosbuvir and ruzasvir in healthy participants. Poster 1879. Presented at the Liver Meeting; 2023 Nov 10-14; Boston (MA, USA)."}],"container-title":["Expert Opinion on Investigational Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13543784.2024.2305137","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T05:21:15Z","timestamp":1727241675000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13543784.2024.2305137"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,2]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1,2]]}},"alternative-id":["10.1080\/13543784.2024.2305137"],"URL":"https:\/\/doi.org\/10.1080\/13543784.2024.2305137","relation":{},"ISSN":["1354-3784","1744-7658"],"issn-type":[{"value":"1354-3784","type":"print"},{"value":"1744-7658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,2]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieid20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieid20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-09-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-10","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-24","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}